Free Trial

Eton Pharmaceuticals Q2 2023 Earnings Report

Eton Pharmaceuticals logo
$14.41 +0.13 (+0.91%)
As of 01/17/2025 04:00 PM Eastern

Eton Pharmaceuticals EPS Results

Actual EPS
$0.18
Consensus EPS
-$0.09
Beat/Miss
Beat by +$0.27
One Year Ago EPS
N/A

Eton Pharmaceuticals Revenue Results

Actual Revenue
$12.00 million
Expected Revenue
$6.50 million
Beat/Miss
Beat by +$5.50 million
YoY Revenue Growth
N/A

Eton Pharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Eton Pharmaceuticals Earnings Headlines

Research Analysts Offer Predictions for ETON Q1 Earnings
Bitcoin to $200K?
Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. Today, he says there's a much smaller crypto – trading for less than $1 – that's likely to deliver way bigger gains than Bitcoin.
See More Eton Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eton Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eton Pharmaceuticals and other key companies, straight to your email.

About Eton Pharmaceuticals

Eton Pharmaceuticals (NASDAQ:ETON), a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

View Eton Pharmaceuticals Profile

More Earnings Resources from MarketBeat